GP Mast 100

GP Mast 100 – Drostanolone Propionate Overview

GP Mast 100 is an injectable anabolic steroid from Geneza Pharmaceuticals containing Drostanolone Propionate at 100 mg/ml in a 10 ml vial. Drostanolone Propionate is a DHT-derived compound sold under the brand name Masteron. The short Propionate ester gives it a half-life of approximately 2-3 days, requiring EOD injections for stable blood levels – the same injection frequency as Testosterone Propionate and Trenbolone Acetate, making it a natural ester-matched companion in the classic short-ester cutting trinity. Commonly searched as Masteron, Mast 100, Masteron Prop, Drostanolone Propionate, Drost Prop, and Geneza Masteron.

What Is Drostanolone Propionate?

Drostanolone Propionate is a DHT (dihydrotestosterone) derivative originally developed for medical use. As a DHT-based compound, it does not aromatize to estrogen – a defining pharmacological property that distinguishes it from testosterone-based injectables. Community references frequently discuss Masteron’s mild anti-estrogenic properties in the context of managing estrogen alongside aromatizing compounds in a cycle. Drostanolone Propionate is primarily referenced in cutting, hardening, and pre-contest frameworks – its most discussed attribute is a hardening and drying effect on physique, particularly cited when combined with low body fat. The Propionate ester produces a half-life of approximately 2-3 days; the Enanthate ester (Drostanolone Enanthate / Masteron E / GP Mast 200) extends this to approximately 7-10 days with a twice-weekly injection schedule.

Why Users Search for GP Mast 100

Masteron Propionate is primarily searched in cutting, pre-contest, and body hardening contexts. The classic short-ester cutting trinity – Testosterone Propionate + Trenbolone Acetate + Drostanolone Propionate – is one of the most consistently referenced competitive bodybuilding cycle frameworks, and Mast 100 occupies the Drostanolone position in that stack. Its non-aromatizing, DHT-derived profile and EOD compatibility with other short-ester compounds are the primary practical reasons it is referenced alongside Test Prop and Tren Ace. Comparison searches between Masteron Propionate and Masteron Enanthate (ester differences, injection frequency, clearance) are a consistent search angle. GP Andromix is the pre-blended trinity version combining Drostanolone Propionate, Testosterone Propionate, and Trenbolone Acetate in a single vial.

• Active substance: Drostanolone Propionate – DHT-derived, non-aromatizing injectable anabolic compound.
• Concentration: 100 mg/ml in a 10 ml vial – 1000 mg Drostanolone Propionate total content.
• Injection schedule: EOD injections referenced for blood level stability with the short Propionate ester.
• Common names: Masteron, Mast 100, Masteron Prop, Masteron Propionate, Drostanolone Prop, Drost Prop, Geneza Masteron.
• Cycle context: Short-ester cutting trinity (Test Prop + Tren Ace + Mast 100), pre-contest and hardening stack reference.

GP Mast 100 Dose and Concentration Information

GP Mast 100 is listed at 100 mg/ml. A 10 ml vial contains 1000 mg Drostanolone Propionate in total. The Propionate ester produces a half-life of approximately 2-3 days, making EOD injections the most consistently referenced schedule for maintaining stable blood levels. This matches the injection frequency of Testosterone Propionate and Trenbolone Acetate – the practical basis for the short-ester cutting trinity stack compatibility.

Concentration and Ester Context

100 mg/ml is the standard concentration for injectable Drostanolone Propionate. The Propionate ester’s short half-life requires more frequent injections than the Enanthate ester (Masteron E / GP Mast 200, 200 mg/ml, half-life approximately 7-10 days with twice-weekly dosing), but allows faster clearance – PCT can begin 3-5 days after the last Mast 100 injection, consistent with the other Propionate-ester compounds it is typically stacked with. Blood levels stabilize more quickly with the Propionate ester than with Masteron Enanthate, which requires a longer loading period before peak concentrations are reached.

Bloodwork and Monitoring Context

Drostanolone Propionate does not aromatize, so estrogen-specific bloodwork is not attributed to Masteron itself – however, when used alongside testosterone compounds, estrogen monitoring remains relevant for the aromatizing components of the cycle. DHT-related markers and androgenic side effect monitoring (hair loss assessment, acne) are cited alongside standard lipid panel and hematocrit markers. Masteron does not produce significant liver stress. HPTA suppression occurs with Drostanolone Propionate – post-cycle therapy is referenced after Mast-containing cycles.

• Concentration: 100 mg/ml – standard Drostanolone Propionate injectable concentration.
• Total content: 1000 mg Drostanolone Propionate per 10 ml vial.
• Injection schedule: EOD injections most consistently referenced for blood level stability with the Propionate ester.
• PCT timing: 3-5 days post-last-injection – aligned with the short Propionate ester clearance.
• Bloodwork context: Lipid panel, hematocrit, androgenic markers – no significant liver or estrogen-specific concerns attributed to Masteron itself.
• Ester comparison: GP Mast 200 (Drostanolone Enanthate) offers twice-weekly injections at the cost of slower clearance and later PCT start.